Actively Recruiting
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Led by Hospices Civils de Lyon · Updated on 2021-07-16
410
Participants Needed
17
Research Sites
474 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric acids during digestion. It is also important for the regulation of cell growth of the gastric mucosal. In a healthy person, progastrin is not detectable in the peripheral blood. However, progastrin is abnormally released in the blood of patients with different cancers (colorectal, gastric, ovarian, breast, cervix uterus, melanoma…) The gene GAST coding for progastrin is a direct target gene of the WNT/ß-catenin oncogenic pathway. The activation of this oncogenic pathway is an early event in cancer development. Chronic activation of the WNT/ß-catenin oncogenic pathway occurs in almost all human solid tumors and is a central mechanism in cancer biology that induces cellular proliferation, blocking of differentiation leading to primary tumor growth and metastasis formation. Progastrin measured in the peripheral blood of patients on treatments, could be a new powerful marker for diagnosis and prognosis at different stages.
CONDITIONS
Official Title
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically and/or cytologically confirmed cancers including breast, gastric, renal, prostate, lung, hepatocellular, colorectal, head and neck, thyroid, pancreatic, ovarian, glioblastoma, endometrial, bladder, esophageal, and diffuse large B-cell lymphoma
- Age 18 years or older
- Written informed consent to participate
- Affiliation with a social insurance regime
- For curative treatment strategy patients: planned treatment with curative intent (surgery, radiotherapy, chemotherapy, hormonotherapy, targeted agents), no prior anticancer treatments for the current cancer except prior curative treatments without systemic chemotherapy with at least 6 months remission
- For non-curative treatment strategy patients: planned treatment with non-curative intent (radiotherapy, chemotherapy, hormonotherapy, immunotherapy, targeted agents, non-curative surgery), no prior anticancer treatments in the non-curative setting except for metastatic hormone-sensitive prostate cancer
- Specific tumor-type criteria including invasive breast carcinoma, gastric adenocarcinoma types, renal cancer histologies, prostate cancer high-risk localized stages, lung cancer stages and treatments, hepatocellular carcinoma typical imaging diagnosis, colorectal carcinoma with metastases, head and neck squamous cell carcinoma, differentiated thyroid carcinoma planned for iodine treatment, pancreatic adenocarcinoma planned for surgery, ovarian adenocarcinoma or carcinosarcoma with platinum-sensitive relapse, glioblastoma planned for surgery and adjuvant therapy, endometrial cancer types planned for non-curative systemic treatment, bladder cancer muscle invasive planned for chemotherapy or immunotherapy, superficial oesophago-gastric carcinomas planned for endoscopic surgery, and diffuse large B-cell lymphoma planned for R-CHOP treatment
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
Service de NEURO-ONCOLOGIE du Groupement Hospitalier EST
Bron, France
Actively Recruiting
2
Service d'ONCOLOGIE DIGESTIVE et HEPATOLOGIE de l'hôpital de la Croix-Rousse
Lyon, France
Actively Recruiting
3
Service d'ONCOLOGIE DIGESTIVE et HEPATOLOGIE de l'Hôpital E. Herriot
Lyon, France
Actively Recruiting
4
Service d'Oto-Rhino-Laryngologie de l'Hôpital de la Croix-Rousse
Lyon, France
Actively Recruiting
5
Service d'Urologie de l'Hôpital E. Herriot
Lyon, France
Actively Recruiting
6
Service de Gynécologie de l'hôpital de la Croix-Rousse
Lyon, France
Actively Recruiting
7
Service de Gynécologie du Groupement Hospitalier Est
Lyon, France
Actively Recruiting
8
Service de Pneumologie de l'hôpital de la Croix-Rousse
Lyon, France
Actively Recruiting
9
Service de Pneumologie du Groupement Hospitalier Est
Lyon, France
Actively Recruiting
10
Service d'Hématologie de l'Hôpital Lyon Sud
Pierre-Bénite, France
Actively Recruiting
11
Service d'ONCOLOGIE DIGESTIVE et HEPATOLOGIE du Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Actively Recruiting
12
Service d'Oncologie médicale du Centre hospitalier Lyon Sud
Pierre-Bénite, France
Actively Recruiting
13
Service d'Urologie de l'hôpital Lyon Sud
Pierre-Bénite, France
Actively Recruiting
14
Service de Chirurgie de l'hôpital Lyon Sud
Pierre-Bénite, France
Actively Recruiting
15
Service de Dermatologie de l'hôpital Lyon Sud
Pierre-Bénite, France
Actively Recruiting
16
Service de Gynécologie de l'hôpital Lyon Sud
Pierre-Bénite, France
Actively Recruiting
17
Service de Pneumologie de l'Hôpital Lyon Sud
Pierre-Bénite, France
Actively Recruiting
Research Team
B
Benoit YOU, MD
CONTACT
S
Sara CALATTINI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here